A new drug has demonstrated the ability to functionally cure many hepatitis B infections by suppressing blood viral loads to undetectable levels, significantly reducing transmission risks and complications like cirrhosis. However, because dormant viral genetic material remains embedded in the patient's liver DNA, the virus is not completely eradicated and transient replication flare-ups remain a risk.